Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026
Company

Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany

Fineline Cube Oct 10, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease

Fineline Cube Oct 10, 2023

AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive...

Company Drug

Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease

Fineline Cube Oct 10, 2023

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...

Company

AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit

Fineline Cube Oct 10, 2023

Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...

Company Deals

AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China

Fineline Cube Oct 10, 2023

AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189

Fineline Cube Oct 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...

Company Drug

J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial

Fineline Cube Oct 10, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...

Company Deals

BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal

Fineline Cube Oct 10, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...

Company Deals

Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology

Fineline Cube Oct 9, 2023

The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...

Company Deals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million

Fineline Cube Oct 9, 2023

Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...

Company Drug

Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4

Fineline Cube Oct 9, 2023

Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...

Company Drug

FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment

Fineline Cube Oct 9, 2023

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...

Company Deals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Fineline Cube Oct 9, 2023

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...

Policy / Regulatory

Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030

Fineline Cube Oct 9, 2023

The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...

Company Deals

ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform

Fineline Cube Oct 9, 2023

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...

Company Deals

Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China

Fineline Cube Oct 9, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand...

Company Deals

Chongqing Zhifei Partners with GSK for Shingrix Distribution in China

Fineline Cube Oct 9, 2023

China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and...

Company Deals

Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador

Fineline Cube Oct 9, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...

Company Drug

Innovent Biologics Doses First Patient in Phase 3 Study of IBI302 for Neovascular AMD

Fineline Cube Oct 9, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient with neovascular age-related...

Policy / Regulatory

NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management

Fineline Cube Oct 9, 2023

The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...

Posts pagination

1 … 511 512 513 … 714

Recent updates

  • WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
  • Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
  • Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Company Deals

Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.